The Value of Implantable Cardioverter-Defibrillators in Managing Atrial Fibrillation by Frisch, Daniel
Thomas Jefferson University
Jefferson Digital Commons
Cardiology Faculty Papers Department of Cardiology
Winter 1-1-2009
The Value of Implantable Cardioverter-
Defibrillators in Managing Atrial Fibrillation
Daniel Frisch
Thomas Jefferson University, daniel.frisch@jefferson.edu
Let us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/cardiologyfp
Part of the Cardiology Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Cardiology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
This editorial is the authors' final version prior to publication in Heart Rhythm Volume 6, Issue 1, January 2009, Pages 9-10. The
published version is available at . DOI: 10.1016/j.hrthm.2008.10.009. Copyright © Elsevier Inc..
As submitted to Heart Rhythm and later published as:  Heart Rhythm, 
Volume 6, Issue 1, January 2009, 9-10. 
DOI: 10.1016/j.hrthm.2008.10.009 
 
The Value of Implantable Cardioverter Defibrillators in Managing Atrial 
Fibrillation  
Daniel Frisch, M.D. 
 
 
Atrial fibrillation (AF) is associated with an increased risk of mortality as well as 
significant morbidity including bothersome symptoms, exacerbation of heart failure, and 
thromboembolic events. 1 2-6   Explanations for the mortality risk are variable, but the 
majority opinion favors AF as a marker of reduced health status, especially 
cardiovascular health.6, 7  
 
In patients with congestive heart failure (CHF) AF is especially problematic.  Atrial 
fibrillation may occur in 10% to 30% of patients and is associated with both a reduction 
in exercise capacity and a worsened long-term prognosis. 8 9 As CHF class increases 
there is a concomitant rise in the prevalence of AF, which often adversely affects 
outcome. 9 10   A particular harbinger of poor outcome is the new diagnosis of AF in 
patients with CHF.  These patients require additional medical attention as they are at 
increased risk of mortality.11 12-14  
 
The diagnosis of atrial fibrillation can be made in several ways, most often by 
electrocardiography, when patients present with sypmptoms.15, 16    In more than 10-25% 
of patients, however, AF is discovered in the absence of symptoms or after a 
complication attributable to AF.7, 17  An obvious limitation of relying on symptoms and of 
episodic screening for AF is that silent episodes may occur during periods without 
observation. 
 
In an era where the indications for implantable devices continue to grow, along with the 
ability to perform sophisticated telemetry monitoring, it is not surprising that AF is being 
diagnosed during routine device interrogation.  Importantly, device-derived atrial high 
rate episodes correlate with true AF diagnosis.18, 19  In one study, 38% of patients with a 
history of AF had episodes of AF lasting more than 48 hours noted at the time of 
interrogation despite these patients being asymptomatic and in sinus rhythm at the time of 
evaluation.20   In patients receiving pacemakers for sinus node dysfunction up to 68% 
may have device-documented AF over time.21   This is especially true in patients with a 
history of AF.  In one cohort without documented AF prior to implant, atrial high-rate 
episodes lasting longer than 5 minutes were noted in 29% of the patients.22  Furthermore, 
detection of atrial high-rate events in devices is a predictor of poor outcome.23   Based on 
these observations, it is likely that the current estimates of AF prevalence in the general 
population may eventually be revised upward.  
 
In this issue of the Journal, Dr. Bunch et al. have submitted an analysis from the 
Inhibition of Unnecessary RV Pacing with AV Search Hysteresis in ICDs (INTRINSIC 
RV) study that evaluated newly-detected AF (as diagnosed by the proprietary Atrial 
Rhythm Classification algorithm) in patients with and without a history of AF.24  Over 
80% of the cohort had New York Heart Association (NYHA) Class II heart failure or 
greater.  In an unadjusted model comparing patients with and without a history of AF, the 
cohort with prior AF had significantly more CHF hospitalizations, death, and ICD 
shocks.  After adjustment for baseline characteristics these differences were attenuated, 
and after further adjustment for medication differences, there were no statistical 
differences.  It is interesting that adjustment for medication differences eliminated the 
differences in death, CHF hospitalization, and ICD shocks between the groups with and 
without a history of AF.  The authors consider that effective medication use may have 
mitigated the cardiovascular risk factors that would have predisposed to adverse 
outcomes.  This finding stands in contrast to observations made by others, which have 
shown increased ICD therapies, heart failure progression, and mortality in patients with a 
history of AF.25, 26  The disparity possibly reflects differences in medication use and 
modification of other co-morbidities. 
 
An additional observation was that new-onset AF during the first three months after 
implant in patients without a prior history of AF (45 of 1170, 4%) was associated with a 
significant increased risk of death [HR 2.86, p=0.05] but not with inappropriate ICD 
shock or CHF hospitalization after adjustment.  In the group without a history of AF there 
was a 3.2% incidence of death (n=36) when no AF was documented and an 8.9% 
incidence (n=4) when AF was diagnosed within the first 3 months after implant.  Though 
the numbers are small, these patients may represent a particularly high-risk group.  
Although the duration of the AF episodes is not stated, this may be of some relevance.   
In an analysis of the Mode Selection Trial (MOST), atrial high event rate episodes of 5 
minutes or longer predicted an increased risk of cardiovascular events including stroke.23   
In contrast, another study looking at the duration of atrial high rate events, found that 
only episodes lasting longer than one day increased risk.27  
 
The investigators also noted that 12% of the cohort received an ICD shock during the 
first 3 months after implantation.  Occurrence of a shock was associated with an increase 
in hospitalization for CHF and for subsequent shocks, but not death.  In a similar 
population that was followed longer, the presence of any shock carried a higher risk of 
death.28  Both reports are reminders that any ICD shock carries the potential for 
unfavorable consequences in patients with left ventricular dysfunction.  
 
An important limitation, voiced by the authors, bears emphasis which is that up to a third 
of patients with “new-onset AF,” may have had AF prior to device implantation. The 
analyses presented in this paper should be interpreted cautiously in light of this scenario. 
 
Overall there are three relevant findings in this study.  First, aggressive medical therapy 
may mitigate the negative impact of AF in ICD patients, possibly by addressing 
underlying cardiovascular issues and possibly by avoiding inappropriate shocks.  Second, 
the development of AF may herald an adverse change in clinical status necessitating 
intensification of care.  Finally, this report reiterates the value of implanted devices to 
serve as patient monitors, in addition to their ability to deliver therapy, and compels 
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